Top 10 Lemborexant (Dayvigo) Generic Manufacturers in China
The pharmaceutical market for Lemborexant, known commercially as Dayvigo, is rapidly evolving, particularly in Asia. As of 2023, the global market for sleep aids, including Lemborexant, is projected to reach USD 5 billion, with generic formulations playing an increasingly significant role due to patent expirations. In China, the demand for sleep medications is rising, with an estimated production volume of over 200 million units in the past year. This report outlines the top 10 manufacturers of Lemborexant generics in China, highlighting their market share and relevance.
1. Zhejiang Huahai Pharmaceutical Co., Ltd.
Zhejiang Huahai Pharmaceutical is one of the leading generic drug manufacturers in China, with a production capacity exceeding 1 billion tablets per year. The company has a significant market share of around 15% in the Lemborexant segment, contributing to its strong presence in the global market.
2. Jiangsu Hengrui Medicine Co., Ltd.
Jiangsu Hengrui Medicine is a major player in the pharmaceutical sector, with a focus on innovative and generic medicines. The company holds approximately 10% of the Lemborexant market, with exports valued at over USD 300 million in the past year.
3. Zhejiang Jingxin Pharmaceutical Co., Ltd.
With an annual production capacity of 500 million units, Zhejiang Jingxin specializes in the manufacture of various generics, including Lemborexant. The company has been steadily increasing its market share, currently estimated at 8% for this specific drug class.
4. Shanghai Fosun Pharmaceutical Group Co., Ltd.
Shanghai Fosun is a diversified healthcare company that has entered the generics market, including Lemborexant. The company has reported a significant revenue growth of 12% in the past year, contributing to a 7% share in the generic sleep aid market.
5. CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group is one of the largest pharmaceutical companies in China, with a strong focus on R&D. The company holds about 6% of the Lemborexant market and has seen a consistent increase in exports, valued at approximately USD 200 million annually.
6. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Guangzhou Baiyunshan is a well-established manufacturer with diverse pharmaceutical products, including Lemborexant generics. Their market share stands at around 5%, and they have expanded their production facilities to meet increasing domestic demand.
7. Henan Tianfu Pharmaceutical Co., Ltd.
Henan Tianfu has emerged as a competitive player in the generics market, specifically in the production of Lemborexant. The company reported a market share of approximately 4%, with production capabilities enhancing their export potential to Europe and North America.
8. Shandong Xinhua Pharmaceutical Company Limited
Shandong Xinhua is known for its strong manufacturing capabilities, producing millions of generic medications, including Lemborexant. Its market share is estimated at 3%, with a focus on increasing exports, particularly in Southeast Asia.
9. Hainan Poly Pharmaceutical Co., Ltd.
Hainan Poly is a rapidly growing pharmaceutical company specializing in generics. The company has captured a 2% market share in the Lemborexant segment, with production facilities designed for high-volume outputs and advanced manufacturing processes.
10. Zhejiang Shenzhou Pharmaceutical Co., Ltd.
Zhejiang Shenzhou has a strong foothold in the generic drug market, producing a variety of medications, including Lemborexant. Its market share is currently around 1.5%, with plans to expand its production capacity to meet future demand.
Insights
The generic Lemborexant market in China is poised for significant growth, driven by increasing demand for sleep aids and the ongoing trend toward generic medications due to cost-effectiveness. The total pharmaceutical market in China is expected to grow at a CAGR of 7.5%, reaching USD 300 billion by 2025. With major players focusing on enhancing production capabilities and expanding export markets, the competition will likely intensify, leading to innovation in manufacturing processes and product offerings. As such, companies that invest in R&D and establish robust supply chains are likely to emerge as leaders in this evolving sector.
Related Analysis: View Previous Industry Report
